Differences in susceptibility of circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 to neutralization by convalescent plasma or vaccinee (Sinopharm or Sinovac) serum

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization – New England Journal of Medicine

Related studies: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination – Nature Medicine AND Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. AND RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant AND New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments AND Moderna COVID-19 vaccine may be less effective against variant found in South Africa

Commentary on Twitter

Lab study on vaxes & variants, testing blood samples: Sinopharm's Beijing vax & Sinovac's CoronaVac (1st study). Both held up reasonably with B.1.1.7 ("UK") variant of concern; both found B.1.351 ("SA") challenging https://t.co/X10ZnpSsrZ
40 of these now: https://t.co/Kwo742xWBm

— Hilda Bastian, PhD (@hildabast) April 7, 2021